Last checked at 
(Sharecast News) - Graphene nanoplatelets supplier Directa Plus said on Thursday that it had continued to make "good progress" during the second half of 2020, with orders and agreements signed across all verticals.
Directa stated it was "confident" of achieving total revenues for the year of approximately €6.0m, exceeding current consensus market expectations, thanks primarily to sales of its G+ enhanced face masks.
The AIM-listed group also highlighted that it had seen an increase in manufacturing capability and a decrease in maintenance costs after being granted a second patent on the equipment used for the super-expansion of intercalated natural graphite in its core plasma technology.
Chief executive Giulio Cesareo said: "This has been an unusual and challenging year, but we are pleased with the growth that we have achieved and the commercial progress we have made despite the worldwide economic uncertainty caused by the coronavirus.
"We look forward with great anticipation to 2021 and to further future success."
As of 1055 GMT, Directa shares were up 2.11% at 82.20p.
4 Apr 2022 10:20
IN BRIEF: Directa Plus wins EPA approval for Grafysorber use in US
Directa Plus PLC - London-based graphene nanoplatelets supplier - Says it has received authorisation from the US Environmental Protection Agency for its Grafysorber technology.
Read more